Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma

Aska Drljevic-Nielsen; Finn Rasmussen; Patricia Switten Nielsen; Christina Stilling; Kennet Thorup; Jill Rachel Mains; Hans Henrik Torp Madsen; Frede Donskov

doi:10.1186/s41747-021-00232-2

Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma

Aska Drljevic-Nielsen^*, Finn Rasmussen, Patricia Switten Nielsen, Christina Stilling, Kennet Thorup, Jill Rachel Mains, Hans Henrik Torp Madsen, Frede Donskov

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Abstract

Background: Angiogenesis is prominent in metastatic renal cell carcinoma (mRCC). We compared two angiogenesis assessment methods: dynamic contrast-enhanced computed tomography (DCE-CT)-derived blood volume (BV) and blood flow (BF) and core biopsy microvessel density (MVD). Methods: As planned in DaRenCa Study-1 study, DCE-CT and core biopsy were performed from the same tumour/metastasis at baseline. MVD was assessed by CD34 immunostaining in tumour (CD34-index_T) or tumour including necrosis (CD34-index_TN). BV and BF were assessed using the DCE-CT software. Overall survival (OS) and progression-free survival (PFS) were assessed by Kaplan-Meier analysis. Spearman coefficient (rho) tested the correlation between MVD and BV, BF, or CT density (HU). Results: At baseline, 25 patients had analysable scans and tissue. BV_deconv, BV_Patlak, and BF_deconv > median were associated with favourable OS (43.2 versus 14.6 months, p = 0.002; 31.6 versus 20.2 months, p = 0.015; and 31.6 versus 24.5 months, p = 0.019). CD34-index_T and CD34-index_TN did not correlate with age (p = 0.543), sex (p = 0.225), treatment (p = 0.848), International mRCC Database Consortium category (p = 0.152), synchronous versus metachronous metastatic disease (p = 0.378), or tumour volume (p = 0.848). CD34-index_T or CD34-index_TN > median was not associated with PFS (p = 0.441 and p = 0.854, respectively) or OS (p = 0.987 and p =0.528, respectively). CD34-index_T or CD34-index_TN was not correlated with BV, BF, or HU (rho 0.20–0.26). Conclusions: Differently from MVD, DCE-CT-derived BV and BF had prognostic impact and may better reflect angiogenesis in mRCC. Trial registration: NCT01274273

Originalsprog	Engelsk
Artikelnummer	32
Tidsskrift	European Radiology Experimental
Vol/bind	5
Nummer	1
DOI	https://doi.org/10.1186/s41747-021-00232-2
Status	Udgivet - jul. 2021

Adgang til dokumentet

10.1186/s41747-021-00232-2

Andre filer og links

Link to publication in Scopus

Citationsformater

Drljevic-Nielsen, A., Rasmussen, F., Nielsen, P. S., Stilling, C., Thorup, K., Mains, J. R., Madsen, H. H. T., & Donskov, F. (2021). Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma. European Radiology Experimental, 5(1), Artikel 32. https://doi.org/10.1186/s41747-021-00232-2

@article{e130eccd46bd4e79b9fc3559fb3ce3ec,

title = "Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma",

abstract = "Background: Angiogenesis is prominent in metastatic renal cell carcinoma (mRCC). We compared two angiogenesis assessment methods: dynamic contrast-enhanced computed tomography (DCE-CT)-derived blood volume (BV) and blood flow (BF) and core biopsy microvessel density (MVD). Methods: As planned in DaRenCa Study-1 study, DCE-CT and core biopsy were performed from the same tumour/metastasis at baseline. MVD was assessed by CD34 immunostaining in tumour (CD34-indexT) or tumour including necrosis (CD34-indexTN). BV and BF were assessed using the DCE-CT software. Overall survival (OS) and progression-free survival (PFS) were assessed by Kaplan-Meier analysis. Spearman coefficient (rho) tested the correlation between MVD and BV, BF, or CT density (HU). Results: At baseline, 25 patients had analysable scans and tissue. BVdeconv, BVPatlak, and BFdeconv > median were associated with favourable OS (43.2 versus 14.6 months, p = 0.002; 31.6 versus 20.2 months, p = 0.015; and 31.6 versus 24.5 months, p = 0.019). CD34-indexT and CD34-indexTN did not correlate with age (p = 0.543), sex (p = 0.225), treatment (p = 0.848), International mRCC Database Consortium category (p = 0.152), synchronous versus metachronous metastatic disease (p = 0.378), or tumour volume (p = 0.848). CD34-indexT or CD34-indexTN > median was not associated with PFS (p = 0.441 and p = 0.854, respectively) or OS (p = 0.987 and p =0.528, respectively). CD34-indexT or CD34-indexTN was not correlated with BV, BF, or HU (rho 0.20–0.26). Conclusions: Differently from MVD, DCE-CT-derived BV and BF had prognostic impact and may better reflect angiogenesis in mRCC. Trial registration: NCT01274273",

keywords = "Blood volume, Carcinoma (renal cell), Microvascular density, Prognosis, Tomography (x-ray computed)",

author = "Aska Drljevic-Nielsen and Finn Rasmussen and Nielsen, {Patricia Switten} and Christina Stilling and Kennet Thorup and Mains, {Jill Rachel} and Madsen, {Hans Henrik Torp} and Frede Donskov",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = jul,

doi = "10.1186/s41747-021-00232-2",

language = "English",

volume = "5",

journal = "European Radiology Experimental",

issn = "2509-9280",

publisher = "Springer Open",

number = "1",

}

Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma. / Drljevic-Nielsen, Aska; Rasmussen, Finn; Nielsen, Patricia Switten et al.
I: European Radiology Experimental, Bind 5, Nr. 1, 32, 07.2021.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma

AU - Drljevic-Nielsen, Aska

AU - Rasmussen, Finn

AU - Nielsen, Patricia Switten

AU - Stilling, Christina

AU - Thorup, Kennet

AU - Mains, Jill Rachel

AU - Madsen, Hans Henrik Torp

AU - Donskov, Frede

PY - 2021/7

Y1 - 2021/7

N2 - Background: Angiogenesis is prominent in metastatic renal cell carcinoma (mRCC). We compared two angiogenesis assessment methods: dynamic contrast-enhanced computed tomography (DCE-CT)-derived blood volume (BV) and blood flow (BF) and core biopsy microvessel density (MVD). Methods: As planned in DaRenCa Study-1 study, DCE-CT and core biopsy were performed from the same tumour/metastasis at baseline. MVD was assessed by CD34 immunostaining in tumour (CD34-indexT) or tumour including necrosis (CD34-indexTN). BV and BF were assessed using the DCE-CT software. Overall survival (OS) and progression-free survival (PFS) were assessed by Kaplan-Meier analysis. Spearman coefficient (rho) tested the correlation between MVD and BV, BF, or CT density (HU). Results: At baseline, 25 patients had analysable scans and tissue. BVdeconv, BVPatlak, and BFdeconv > median were associated with favourable OS (43.2 versus 14.6 months, p = 0.002; 31.6 versus 20.2 months, p = 0.015; and 31.6 versus 24.5 months, p = 0.019). CD34-indexT and CD34-indexTN did not correlate with age (p = 0.543), sex (p = 0.225), treatment (p = 0.848), International mRCC Database Consortium category (p = 0.152), synchronous versus metachronous metastatic disease (p = 0.378), or tumour volume (p = 0.848). CD34-indexT or CD34-indexTN > median was not associated with PFS (p = 0.441 and p = 0.854, respectively) or OS (p = 0.987 and p =0.528, respectively). CD34-indexT or CD34-indexTN was not correlated with BV, BF, or HU (rho 0.20–0.26). Conclusions: Differently from MVD, DCE-CT-derived BV and BF had prognostic impact and may better reflect angiogenesis in mRCC. Trial registration: NCT01274273

AB - Background: Angiogenesis is prominent in metastatic renal cell carcinoma (mRCC). We compared two angiogenesis assessment methods: dynamic contrast-enhanced computed tomography (DCE-CT)-derived blood volume (BV) and blood flow (BF) and core biopsy microvessel density (MVD). Methods: As planned in DaRenCa Study-1 study, DCE-CT and core biopsy were performed from the same tumour/metastasis at baseline. MVD was assessed by CD34 immunostaining in tumour (CD34-indexT) or tumour including necrosis (CD34-indexTN). BV and BF were assessed using the DCE-CT software. Overall survival (OS) and progression-free survival (PFS) were assessed by Kaplan-Meier analysis. Spearman coefficient (rho) tested the correlation between MVD and BV, BF, or CT density (HU). Results: At baseline, 25 patients had analysable scans and tissue. BVdeconv, BVPatlak, and BFdeconv > median were associated with favourable OS (43.2 versus 14.6 months, p = 0.002; 31.6 versus 20.2 months, p = 0.015; and 31.6 versus 24.5 months, p = 0.019). CD34-indexT and CD34-indexTN did not correlate with age (p = 0.543), sex (p = 0.225), treatment (p = 0.848), International mRCC Database Consortium category (p = 0.152), synchronous versus metachronous metastatic disease (p = 0.378), or tumour volume (p = 0.848). CD34-indexT or CD34-indexTN > median was not associated with PFS (p = 0.441 and p = 0.854, respectively) or OS (p = 0.987 and p =0.528, respectively). CD34-indexT or CD34-indexTN was not correlated with BV, BF, or HU (rho 0.20–0.26). Conclusions: Differently from MVD, DCE-CT-derived BV and BF had prognostic impact and may better reflect angiogenesis in mRCC. Trial registration: NCT01274273

KW - Blood volume

KW - Carcinoma (renal cell)

KW - Microvascular density

KW - Prognosis

KW - Tomography (x-ray computed)

UR - http://www.scopus.com/inward/record.url?scp=85111494915&partnerID=8YFLogxK

U2 - 10.1186/s41747-021-00232-2

DO - 10.1186/s41747-021-00232-2

M3 - Journal article

C2 - 34327591

AN - SCOPUS:85111494915

SN - 2509-9280

VL - 5

JO - European Radiology Experimental

JF - European Radiology Experimental

IS - 1

M1 - 32

ER -

Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater